Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-01 plus standard of care versus standard of care in acute-on-chronic liver failure
2024-513706-56-00Phase 2Completed
- Sponsor
- Versantis AG
- Start
- Mar 2023
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial in acute-on-chronic liver failure (ACLF) comparing VS-01 plus standard of care with Standard of care alone (2 arms). Primary endpoint: CLIF-C ACLF score at Day 7. Started Mar 2023; status: completed.
02
Drugs
VS-01-HAC
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on 2024-513706-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513706-56-00.